Abstract
Gallbladder cancer (GBC) is the most fatal cancer of the biliary tract with poor prognosis. Silent in its infancy, this malignancy remains asymptomatic until aggressive disease has progressed to an advanced and non-curative stage. The overall mean survival rate for patients with GBC is less than 6 months, with a 5-year survival rate of approximately 5% with a high relapse rate. Treatment depends upon the stage of disease, patient’s age, nutritional status, performance status, and cardiopulmonary, hepatic, and renal functions. Complete surgical resection is considered the most curative modality for GBC. Chemotherapy has recently shown its effect on gallbladder cancer. Therapeutic agents, targeting cellular and molecular pathways, can effectively impede tumor growth. Newer drugs are being developed that work which target specific parts of cancer cells or their surrounding environments like tumor blood vessels. This chapter discusses market of chemotherapeutic drugs in India and market drives and government initiatives for the promotion of pharmaceutical sector in India with special emphasis on GBC.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aaronson S (1991) Growth factors and Cancer. Science 254(5035):1146–1153
American Cancer Society (2014) Cancer facts & figures 2014. American Cancer Society, Atlanta
American Cancer Society (2017) Cancer facts & figures 2017. American Cancer Society, Atlanta
Anticancer Drugs Market (Drug Type – Cytotoxic Drugs (Alkylating Agents, and Antimetabolites), Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), and Hormonal Drugs; Therapy Type – Chemotherapy, Targeted Therapy, and Immunotherapy; Cancer Type – Lung Cancer, Breast Cancer, Leukemia, and Colorectal Cancer) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017–2025 (2018)
Chaturvedi K, Chataway J, Wield D (2007) Policy, markets and knowledge: strategic synergies in Indian pharmaceutical firms. Tech Anal Strat Manag 19(5):565–588
Czito BG, Hurwitz HI, Clough RW, Tyler DS, Morse MA, Clary BM, Pappas TN, Fernando NH, Willett CG (2005) Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys 62(4):1030–1034
DeStoll M (1788) Rationismendendi, in nosocomiopracticovendobonensi. part 1 lugdunibatavarum, Haak et Socios et A et J Honkoop
Dixit R, Pandey M, Tripathi SK, Dwivedi AND, Shukla VK (2017) Comparative analysis of mutational profile of sonic hedgehog gene in gallbladder cancer. Dig Dis Sci 62(3):708–714
Dixit R, Shukla VK, Pandey M (2012) Molecular alterations in gallbladder cancer. World J Pathol 1:7
Dixit R, Shukla VK (2014) Why is gallbladder cancer common in the Gangetic Belt? In: Perspectives in cancer prevention-translational cancer research. Springer, New Delhi, pp 145–151
Dixit R, Singh G, Pandey M, Basu S, Bhartiya SK, Singh KK, Shukla VK (2016) Association of methylenetetrahydrafolate reductase gene polymorphism (MTHFR) in patients with gallbladder cancer. J Gastrointest Cancer 47(1):55–60
Dixit R (2015) Gene profiling of gallbladder cancer. Ph.D. thesis, Banaras Hindu University, Varanasi, India
Dutta U (2012) Gallbladder cancer. Can newer insights improve the outcome? J Gastroenterol Hepatol 27(4):642–653
Dwivedi AND, Jain S, Dixit R (2015) Gall bladder carcinoma: aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases 3(3):231–244
Frost & Sullivan (2017) Preference to targeted therapies and patient centric approaches drive transformations in oncology drug delivery market
Greene W (2007) The emergence of India’s pharmaceutical industry and implications for the U.S. Generic Drug Market. U.S. International Trade Commission
Houry S, Barrier A, Huguier M (2001) Irradiation therapy for gallbladder carcinoma: recent advances. J Hepato-Biliary-Pancreat Surg 8(6):518–524
Hundal R, Shaffer EA (2014) Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 6:99–109
Indian Pharmaceuticals Industry Report (2019) India brand equity foundation
Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, Haddock MG, Nagorney D (2002) Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 52(1):167–175
Kumar A, Kumar M, Dixit R, Jaiswal R, Srivastava V, Pandey M (2012) Presence of human papilloma virus and EGFR expression does not predict response to neoadjuvant chemotherapy in oral cancer. World J Surg Med Radiat Oncol 1:103–110
McKinsey & Company report (2009) India Pharma 2020: propelling access and acceptance, realising true potential
Mhatre SS, Nagrani RT, Budukh A, Chiplunkar S, Badwe R, Patil P, Laversanne M, Rajaraman P, Bray F, Dikshit R (2016) Place of birth and risk of gallbladder cancer in India. Indian J Cancer 53:304–308
Misra A, Misra S, Chaturvedi A, Srivastava PK (2002) Case report. Orbital metastasis from gall bladder carcinoma. Br J Radiol 75(889):72–73
Misra S, Chaturvedi A, Misra NC, Sharma ID (2003) Carcinoma of the gallbladder. Lancet Oncol 4:167–176
National Cancer Registry Programme (2013) Three years report of population based cancer registries; 2009–2011. Indian Council of Medical Research, New Delhi
National Pharmaceutical Policy (2006) Department of Chemicals 2 and Petrochemicals, Government of India, Dec. 28, 2005
Pandey M, Kannepali KK, Dixit R, Kumar M (2018) Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma. World J Surg Oncol 16:20
Pandey P, Pandey M, Singh KK, Dixit R, Shukla VK (2017) Health related quality of life in patients of the gallbladder cancer with treatment. Int J Biol Med Res 8(2):5948–5953
Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F (2010) Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10:631
Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR (2008) Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol 14(33):5210–5216
Rakić M, Patrlj L, Kopljar M, Kliček R, Kolovrat M, Loncar B, Busic Z (2014) Gallbladder cancer. Hepatobiliary Surg Nutr 3(5):221–226
Shukla VK, Das PC, Dixit R, Bhartiya SK, Basu S, Raman MJ (2012) Study of AP endonuclease (APEX1/REF1), a DNA repair enzyme, in gallbladder carcinoma. Anticancer Res 32(4):1489–1492
Shukla VK, Khandelwal C, Roy SK, Vaidya MP (1985) Primary carcinoma of the gall bladder: a review of a 16-year period at the University Hospital. J Surg Oncol 28(1):32–35
Todoroki T (2000) Chemotherapy for gallbladder carcinoma – a surgeon’s perspective. Hepato-Gastroenterology 47:948–955
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281
Xiu AX, Hong TS, Hezel AF, Kooby DA (2010) Current management of gallbladder carcinoma. Oncologist 15:168–181
Zhao DY, Lim KH (2017) Current biologics for treatment of biliary tract cancers. J Gastrointest Oncol 8(3):430–440
Acknowledgment
RD is grateful to the Department of Health Research, New Delhi, for providing financial support through the Women Scientists Scheme.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Dixit, R., Pandey, M., Pandey, P., Shukla, V.K. (2020). Chemotherapeutic Drugs and Gallbladder Cancer: Market Potential in India. In: Keswani, C. (eds) Bioeconomy for Sustainable Development. Springer, Singapore. https://doi.org/10.1007/978-981-13-9431-7_20
Download citation
DOI: https://doi.org/10.1007/978-981-13-9431-7_20
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-9430-0
Online ISBN: 978-981-13-9431-7
eBook Packages: Earth and Environmental ScienceEarth and Environmental Science (R0)